Skip to main content
Altuviiio logo

Patient Experiences - Morgan


“ALTUVIIIO has worked very well for me.”   
 

A different type of treatment 

I was receiving factor mimetic treatment prior to switching to ALTUVIIIO. I had a health scare that required surgery, so I sought another option.     
 

Overcoming anxiety 

At first, I was anxious about switching. I was worried about getting it covered by insurance. But my doctor and care team helped by reaching out to the Sanofi support team.     
 

Making a successful switch 

Once I made the switch and started ALTUVIIIO, I engaged with my care team twice. That was enough to get me started because I had no issues. The switch was easy for me, and I’ve been doing very well on my new treatment.   
 

Taking a positive approach 

I think doctors and their team can make patients feel comfortable exploring potential treatment options by having a positive attitude and creating a safe space to ask questions. Doctors should ask questions and have an open dialogue with their patients to determine whether switching treatments could be the right choice.

This testimonial reflects one patient’s experience and has not been clinically evaluated. It is not intended to imply typical outcomes or substitute for clinical evidence. Morgan is a promotional speaker compensated by Sanofi. 

Discover More Patient Experiences

Indication

ALTUVIIIO® is indicated for use in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding
Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Contraindications

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions
  • Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. Discontinue use of ALTUVIIIO if hypersensitivity reaction occurs and manage symptoms as appropriate.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of ALTUVIIIO. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.
Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

Indication

Important Safety Information

© 2026 Sanofi. All rights reserved. All trademarks mentioned are the property of the Sanofi group. MAT-US-2508205-v3.0-08/2026 Last Updated: August 2026